Clinical Trial

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-16; most recent amendment 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2025-09-17
Trial Details
NCT Number NCT07082439
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Merck Sharp & Dohme LLC
Conditions Colorectal Adenocarcinoma Metastatic in the Liver
Enrollment 27 participants
Start Date 2025-09-10
Primary Completion 2027-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2025-09-22